Biotechnology

A new drug, divesiran, shows stunning success in trials, offering hope to those with a rare blood cancer by potentially replacing frequent phlebotomies with a quarterly shot.

Amid its pending sale to Zymeworks, Theravance Biopharma’s Q2 results reveal a lesson in resilience, with strong YUPELRI sales and deep cost cuts.

A Korean firm's breakthrough tech bypasses freezing temps for vaccines. This isn't just a business win; it's a blueprint for a more accessible future.

Partner Ocumension submits NCX 470 for approval, a move poised to tap into a massive patient market and validate Nicox's global commercialization strategy.

A key partner's FDA stumble could have derailed a vital new SMA drug. Instead, Scholar Rock's foresight kept the approval on track, showing why it pays to plan for the worst.

Braveheart Bio's stunning IPO debut raised nearly half a billion dollars. We dig into the story behind the numbers and what it signals for the 2026 economy.

A landmark clinical trial for Progressive Supranuclear Palsy has begun. We deconstruct the novel platform design that offers new hope against a devastating disease.

A Utah biotech's new blood test can identify the exact brain cells dying in diseases like Alzheimer's, a major leap beyond today's diagnostics.

With a fresh $30M and a potential $90M total, Femasys is poised to shake up women's health. But can it hit the milestones to unlock its full potential?

BioStem Technologies' move from OTC to Nasdaq marks a pivotal moment, promising greater capital access and visibility for its innovative perinatal allografts.

X4 Pharmaceuticals secures a key European approval and overhauls its pivotal trial, signaling a major strategic shift backed by a newly extended cash runway.

With its Duchenne therapy nearing a pivotal FDA meeting, Solid Biosciences isn't just developing a drug; it's building a network for genetic repair.

With $911M in the bank, Relay Therapeutics is aggressively advancing its precision drug zovegalisib, targeting both breast cancer and rare vascular anomalies.

With late-stage trials underway and a cash runway into 2030, Trevi Therapeutics is accelerating its mission. But what does this mean for millions of unseen sufferers?

Artiva Biotherapeutics secures FDA fast-track status for its novel NK cell therapy, AlloNK. This could revolutionize autoimmune care for millions.

With a $250M decision pending and a major acquisition closing, Zymeworks is betting its future on a radical pivot to a diversified, revenue-generating model.

With its lead obesity drug in late-stage trials and a Novo Nordisk veteran newly hired, Structure Therapeutics is making a calculated play for the oral GLP-1 crown.

With nearly $1B in cash and a shrinking net loss, Janux is pushing its advanced prostate cancer drugs while its novel autoimmune therapy nears a key data reveal.

With a Q3 FDA submission for its novel epilepsy drug azetukalner imminent, Xenon leverages a massive cash runway to expand into neuropsychiatry and pain.

With a $215M war chest and a runway into 2028, Corvus Pharmaceuticals is aggressively advancing its lead drug, soquelitinib, across cancer and immune diseases.